Premium
Cell therapy for neonatal hypoxia–ischemia and cerebral palsy
Author(s) -
Bennet Laura,
Tan Sidhartha,
Van den Heuij Lotte,
Derrick Matthew,
Groenendaal Floris,
van Bel Frank,
Juul Sandra,
Back Stephen A.,
Northington Frances,
Robertson Nicola J.,
Mallard Carina,
Gunn Alistair Jan
Publication year - 2012
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.22670
Subject(s) - medicine , cerebral palsy , hypoxia (environmental) , progenitor cell , hypothermia , ischemia , stem cell , animal studies , stem cell therapy , neuroprotection , cell therapy , anesthesia , bioinformatics , neuroscience , transplantation , psychology , physical medicine and rehabilitation , biology , chemistry , organic chemistry , oxygen , genetics
Abstract Perinatal hypoxic–ischemic brain injury remains a major cause of cerebral palsy. Although therapeutic hypothermia is now established to improve recovery from hypoxia–ischemia (HI) at term, many infants continue to survive with disability, and hypothermia has not yet been tested in preterm infants. There is increasing evidence from in vitro and in vivo preclinical studies that stem/progenitor cells may have multiple beneficial effects on outcome after hypoxic–ischemic injury. Stem/progenitor cells have shown great promise in animal studies in decreasing neurological impairment; however, the mechanisms of action of stem cells, and the optimal type, dose, and method of administration remain surprisingly unclear, and some studies have found no benefit. Although cell‐based interventions after completion of the majority of secondary cell death appear to have potential to improve functional outcome for neonates after HI, further rigorous testing in translational animal models is required before randomized controlled trials should be considered. ANN NEUROL 2012;